Isis reaches new highs on Phase I SMA drug data
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals has seen its fair share of stock price gains this year and the company closed up another 14.1% to reach a new high of $36.27 per share on 19 September on the news that children with spinal muscular atrophy in a Phase I study continued to show benefits up to 14 months after a single intrathecal injection with the two highest doses of ISIS-SMNRx.